Lida Pilot is a platform-based drug developer, based on new chemical proteomics technology, focusing on the development of innovative lead compound libraries and innovative targets. Platform-based technology, which owns a picture-to-chemical structure platform “Huatu”, which provides users with functions such as pasting pictures. Recently, Lida Pilot completed the Pre-A round of financing of nearly US$6 million, led by BlueRun Ventures and followed by Yongchao Ventures. The new funding will be used to advance the development of Leda Pilot’s automated platform for chemical proteomics and the creation of the world’s largest database of target-probe bindings at the human living cell level.
This article is transferred from: https://www.itjuzi.com/investevent/13745046
This site is only for collection, and the copyright belongs to the original author.